Prior studies suggested a role of USP12 in prostate carcinomas, wherein USP12 promoted AR signalling and tumour cell proliferation, as well as therapy resistance, by regulating AR ubiquitination and MDM2-P53 signalling19,20,34. This evidence concerns the gene MDM2 and prostate carcinoma.